Findings

What do systematic reviews say?

4,815 questions · 6,211 findings · 638 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,052 · 16.9%GRADE not reported 441 · 7.1%Very low 1,700 · 27.4%Low 1,651 · 26.6%Moderate 1,070 · 17.2%High 297 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Donepezil 5 mg vs placebo

Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg leads to higher clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (high certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.58 [1.1, 2.27]
2 studies · 712 participants
High

Donepezil 5 mg vs placebo

Functional outcomes · vascular dementia and other vascular cognitive impairments

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 798 participants
Moderate

Donepezil 5 mg vs placebo

Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.22 [0.94, 1.58]
3 studies · 1772 participants
Moderate

Donepezil 5 mg vs placebo

Serious adverse events (excluding death) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in serious adverse events (excluding death) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 0.94 [0.72, 1.22]
3 studies · 1772 participants
Moderate

Donepezil 10 mg/day vs placebo

Cognitive function · vascular dementia and other vascular cognitive impairments

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 608 participants
Moderate

Donepezil 10 mg/day vs placebo

Clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks 7‐point Likert scale · vascular dementia and other vascular cognitive impairments

Donepezil 10 mg showed no clear difference in clinical global impression: CIBIC‐Plus (Improvement) at 24 weeks… compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.15 [0.78, 1.7]
2 studies · 699 participants
Moderate

Donepezil 10 mg/day vs placebo

Functional outcomes · vascular dementia and other vascular cognitive impairments

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 813 participants
Moderate

Donepezil 10 mg/day vs placebo

Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.95 [1.2, 3.15]
2 studies · 813 participants
High

Intervention not reported

MSP compared with IHC · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 913 participants
Moderate

Intervention not reported

Other techniques (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 1209 participants
Very low

Intervention not reported

PSQ compared with IHC · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 871 participants
Low

Intervention not reported

PSQ compared with MSP · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 1119 participants
Low

Intervention not reported

Variants of PSQ · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 876 participants
Very low

Intervention not reported

qMSP (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 765 participants
Very low

Intervention not reported

Bead array (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 81 participants
Very low

Intervention not reported

PCR‐mRNA (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 148 participants
Very low

Intervention not reported

MS‐MLPA (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 48 participants
Very low

Intervention not reported

PCR‐HRM (against MSP or PSQ) · people with glioblastoma undergoing treatment with temozolomide Outcome being predicted: overall survival (time to death)

1 finding from 1 review

Prognostic value of test(s) for O6‐methylguanine–DNA methyltransferase (MGMT) promoter methylation for predicting… 2021 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 309 participants
Very low

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Overall survival · women with recurrent or FIGO stage IVB cervical cancer

Apatinib plus chemotherapy or chemotherapy/brachytherapy showed no clear difference in overall survival compared with chemotherapy or chemotherapy/brachytherapy (low certainty).

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
HR 0.9 [0.51, 1.6]
1 study · 52 participants
Low

Apatinib plus chemotherapy or chemotherapy/brachytherapy vs chemotherapy or chemotherapy/brachytherapy

Specific adverse events: gastrointestinal perforations or fistulae ‐ not reported · women with recurrent or FIGO stage IVB cervical cancer

The review found no eligible studies for this question.

1 finding from 1 review

Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found